Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

9

Revenue 2017

Lantus

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Lantus was produced by Sanofi.

The good, the bad and the ugly

The good, the bad and the ugly

Sanofi’s Lantus (-18.8%), Amgen’s Enbrel (-10.8%) and Gilead’s Harvoni (-48.5%) are among those whose revenues have fallen sharply.

Third time lucky? Sanofi cuts an $11.6bn deal to buy Bioverativ

Third time lucky? Sanofi cuts an $11.6bn deal to buy Bioverativ Sanofi needs to deliver some big new products as it faces a slowdown in diabetes sales following the loss of patent protection for blockbuster Lantus (insulin glargine) and increased competition driving

Novartis doubles down on biosimilars with Biocon alliance

Novartis doubles down on biosimilars with Biocon alliance Biocon meanwhile has launched an insulin glargine biosimilar in Japan to rival Sanofi’s Lantus brand, trastuzumab and Roche’s Avastin (bevacizumab) biosimilars in India and recombinant human insulin, insulin glargine

After some big setbacks, Sanofi talks up its R&D portfolio

After some big setbacks, Sanofi talks up its R&D portfolio Sanofi needs its pipeline to deliver some big-selling products as it faces a slowdown in diabetes sales following the loss of patent protection for blockbuster Lantus (insulin glargine) and increased

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Finding the patient voice
How patients feel and speak about clinical trials...
Six Factors to Consider When Designing Advisory Boards
...
The good, the bad and the ugly
Tracking the pharmaceutical industry’s 2017 evolution and assessing how things may shape up in 2018 - it’s a trilogy of trends...

Infographics